Thursday
|
| 20.30-21.10 |
Introduction
Patric Brennan, Colorado State University, USA:
The Saltsjöbaden Conferences (1990 – 2011); their importance and what we have
learned
|
| |
Friday
|
| 09.00-09.15 |
Welcome
Gunilla Källenius
|
| 09.15-09.50 |
Kristine Arnvig, Mill Hill UK:
Non-coding RNA: the dark matter of mycobacterial gene regulation
|
| 09.50-10.05 |
Or01 Cirillo, Daniela M.
Small non-coding RNAs in Mycobacterium
tuberculosis: experimental discovery and computational target prediction
|
| 10.05-10.40 |
Wilbert Bitter, University Medical Center, The Netherlands:
Characterization of ESX-5, one of the type VII secretion systems
|
| 10.40-10.55 |
Or02 van der Wel, Nicole
ESX-1 mediated translocation to the cytosol
determines pathogenicity of mycobacteria
|
| 10.55-11.40 |
COFFEE/POSTERS |
| 11.40-12.15 |
Mary Jackson, Colorado State University, USA:
Disinfectant-Resistant Mycobacteria
|
| 12.15-12.30 |
Or03 Danilchanka, Olga
Discovery of MtpA, a novel porin in the outer
membrane of Mycobacterium tuberculosis
|
| 12.30-12.45 |
Or04 Arora, Kriti;
Ultrastructural effects of cell wall damaging
agents on Mycobacterium tuberculosis
|
| 12.45-13.45 |
LUNCH/POSTERS |
| 13.45-14.20 |
Martin Rottenberg, Karolinska Institutet, Sweden:
Suppressor of cytokine signalling (SOCS) molecules and their role in tuberculosis
|
| 14.20-14.35 |
Or05 Krishnan, Nitya
Mycobacterium tuberculosis lipids are
associated with lineage specific innate immune responses
|
| 14.35-14.50 |
Or06 Prados-Rosales, Rafael
Mycobacteria release active membrane vesicles
that modulate immune responses in a TLR2-dependent manner in mice
|
| 14.50-15.25 |
Christoph Lange, Research Center Borstel, Germany:
From bench to bedside: The impact of scientific advances on the management of tuberculosis
|
| 15.25-15.40 |
Or07 Raqib, Rubhana
ALS as a potential biomarker for diagnosis
of tuberculosis
|
| 15.40-15.55 |
Or08 Kremer, Laurent
Mycobacterium tuberculosis lipolytic enzymes
as potential biomarkers for the diagnosis of
active tuberculosis
|
| 16.00 |
RECEPTION AT STOCKHOLM CITY HALL
Enjoy a boat trip trough the archipelago to the City Hall where a reception will
take place by courtesy of the city Stockholm and the county of Stockholm at
Stockholm City Hall, the venue for the Nobel Prize dinner.
|
| |
Saturday
|
| 09.00-09.35 |
Erwin Schurr, McGill, Canada:
Host genetic control of infection by Mycobacterium tuberculosis
|
| 09.35-09.50 |
Or09 Boisson-Dupuis, Stephanie
IL-12Rβ1 deficiency in two of fifty children with
severe tuberculosis from Iran, Morocco, and Turkey
|
| 09.50-10.05 |
Or10 Hoal, Eileen G
Association of toll-like receptor 1, 2, 4, 8 and
9 genes with susceptibility to pulmonary tuberculosis
|
| 10.05-10.40 |
Olivier Neyrolles, CNRS-University of Toulouse, France:
Mycobacterium tuberculosis interactions with host macrophages
|
| 10.40-11.25 |
COFFEE/POSTERS |
| 11.25-11.40 |
Or11 Saunders, Bernadette
Mycobacteria infected macrophages release
micro-particles that modulate inflammation
and antigen presentation
|
| 11.40-12.15 |
Sabine Ehrt, Weill Cornell, USA:
Intracellular survival strategies of Mycobacterium tuberculosis
|
| 12.15-12.30 |
Or12 Petruccioli, Elisa
Autophagy modulation by Mycobacterium
tuberculosis after in vitro infection of human
primary macrophages
|
| 12.30-12.45 |
Or13 Mariotti, Sabrina
Mycobacterium tuberculosis may escape
helper T cell recognition by infecting
human fibroblasts
|
| 12.45-13.45 |
LUNCH/POSTERS |
| 13.45-14.20 |
David Russel, Cornell University, NY, USA:
Probing mycobacterial pathogenesis with synthetic phenotypes and chemical genetics |
| 14.20-14.35 |
Or14 Ehlers, Stefan
Granuloma necrosis in tuberculosis is
mediated by interleukin-4 receptor-alpha-dependent mechanisms
|
| 14.35-14.50 |
Or15 Demangel, Caroline
Mycolactone targets the Wiskott-Aldrich
syndrome protein control of skin integrity
|
| 14.50-15.50 |
COFFEE/POSTERS |
| 15.50-16.25 |
Andrea Cooper, Trudeau Institute, USA
Cellular immunity in the mouse model of tuberculosis
|
| 16.25-16.40 |
Or16 Britton, Warwick
Influenza A virus infection impairs BCG-specific T cell responses and mycobacterial
clearance during pulmonary infection with BCG and influenza A virus
|
| 16.40-16.55 |
Or17 Correia-Neves, Margarida
Immune response and T cell recirculation in
infected thymi: two (in)dependent processes?
|
| 16.55-17.30 |
Samuel Behar, Harvard, USA:
Ongoing interaction between innate and clonal immunity lead to host control of
tuberculosis
|
| 17.30-17.45 |
Or18 Portevin, Damien
Human natural killer cells are recruited to
tuberculous lesions and can respond to extracellular mycobacterium tuberculosis
and infected macrophages
|
| 17.45-18.00 |
Or19 Gilleron, Martine
Lipid trimming and CD1e assistance in
mycobacterial phosphatidyl-myo-inositol mannoside presentation by CD1b to
T lymphocytes
|
| 19.30 |
GALA DINNER AT GRAND HOTEL SALTSJÖBADEN |
| |
Sunday
|
| 09.30-09.45 |
Or20 Marrakchi, Hedia
Functional characterization of FadD32, an
attractive target for the development of new
mycobacterial inhibitors
|
| 09.45-10.20 |
Valerie Mizrahi, University of Cape Town, South Africa:
The development of novel screening strains of Mycobacterium tuberculosis for use in
target-led approaches to tuberculosis drug discovery
|
| 10.20-10.55 |
COFFEE/POSTERS |
| 10.55-11.30 |
Rob Warren, Stellenbosch University, South Africa:
New molecular epidemiology insights of tuberculosis in Southern Africa
|
| 11.30-11.45 |
Or21 Sambandan, Dhinakaran
New approach to tuberculosis chemotherapy
using inhibitors of mycobacterium tuberculosis
biofilm formation
|
| 11.45-12.00 |
Or22 Ahmed, Raija
A phase I study using autologous mesenchymal
stem cells as adjunct treatment in patients with
multi- and extensively-drug resistant tuberculosis
|
| 12.00-13.00 |
LUNCH/POSTERS |
| 13.00-13.35 |
Sally Sharpe, Health Protection Agency, UK:
Non-human primate aerosol challenge models of tuberculosis: species comparison and
new readouts for vaccine evaluation
|
| 13.35-13.50 |
Or23 Satti, Iman
Recombinant FP85A inhibits recombinant
MVA85A IFN-γ responses in healthy
BCG-Primed humans
|
| 13.50-14.05 |
Or24 Velmurugan, Kamalakannan
Construction and evaluation of novel
recombinant BCG vaccines
|
| 14.05-14.45 |
Closing session
Barry Bloom, Harvard, USA:
The Nobility of Failure
|
